Authors: Johanna M. Schafer, Brian D. Lehmann, Paula I. Gonzalez-Ericsson, Clayton B. Marshall, J. Scott Beeler, Lindsay N. Redman, Hailing Jin, Violeta Sanchez, Matthew C. Stubbs, Peggy Scherle, Kimberly N. Johnson, Quanhu Sheng, Joseph T. Roland, Joshua A. Bauer, Yu Shyr, Bapsi Chakravarthy, Bret C. Mobley, Scott W. Hiebert, Justin M. Balko, Melinda E. Sanders, Phillip C. C. Liu, Jennifer A. Pietenpol
Published: 2020-03-11
DOI: 10.1126/scitranslmed.aaw8275
Source: Full article
This study demonstrates the potential utility of BET and MEK inhibitors for advanced MYCN-expressing triple-negative breast cancer.